Chemokine Axis as a Therapeutic Target to Enhance the Recruitment of Tregs and Treat Organ-Specific Autoimmune and Inflammatory Diseases

ImmunotherapyVol. 4, No. 1 EditorialChemokine axis as a therapeutic target to enhance the recruitment of Tregs and treat organ-specific autoimmune and inflammatory diseasesJagadeesh BayryJagadeesh BayryInstitut National de la Santé et de la Recherche Médicale, Unité 872, 15 rue de l'Ecole de Médicine, Paris, F-75006, France and Centre de Recherche des Cordeliers, Equipe 16- Immunopathology and therapeutic immunointervention, Université Pierre et Marie Curie – Paris 6, UMR S 872, Paris, F-75006, France and Université Paris Descartes, UMR S 872, Paris, F-75006, France and International Associated Laboratory IMPACT at National Institute of Immunohaemotology, Mumbai, Institut National de la Santé et de la Recherche Médicale, France - Indian council of Medical Research, India. Published Online:13 Dec 2011https://doi.org/10.2217/imt.11.153AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: autoimmune diseasesCCL17CCL22CCR4CD4+CD25+FoxP3+ T cellschemokineimmunotherapyTregsReferences1 Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol.11,7–13 (2010).Crossref, Medline, CAS, Google Scholar2 Shevach EM. Mechanisms of FoxP3+ T regulatory cell-mediated suppression. Immunity30,636–645 (2009).Crossref, Medline, CAS, Google Scholar3 Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood112,1557–1569 (2008).Crossref, Medline, CAS, Google Scholar4 Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol. Sci.30,287–295 (2009).Crossref, Medline, CAS, Google Scholar5 Duc HT. Complex interplays in immune T-cell differentiation and developmental fate determination. Immunotherapy3,1007–1012 (2011).Link, CAS, Google Scholar6 Thornton AM, Korty PE, Tran DQ et al. Expression of helios, an ikaros transcription factor family member, differentiates thymic-derived from peripherally induced FoxP3+ T regulatory cells. J. Immunol.184,3433–3441 (2010).Crossref, Medline, CAS, Google Scholar7 Tang Q, Bluestone JA. The FoxP3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol.9,239–244 (2008).Crossref, Medline, CAS, Google Scholar8 Andre S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am. J. Pathol.174,1575–1587 (2009).Crossref, Medline, CAS, Google Scholar9 Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol.7,585–598 (2007).Crossref, Medline, CAS, Google Scholar10 Ohkura N, Hamaguchi M, Sakaguchi S. FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents. Trends Pharmacol. Sci.32,158–166 (2011).Crossref, Medline, CAS, Google Scholar11 Chen W. Tregs in immunotherapy: opportunities and challenges. Immunotherapy3,911–914 (2011).Link, Google Scholar12 Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J. Exp. Med.204,33–39 (2007).Crossref, Medline, CAS, Google Scholar13 Strisciuglio C, van Deventer S. Regulatory T cells as potential targets for immunotherapy in inflammatory bowel disease. Immunotherapy2,749–752 (2010).Link, CAS, Google Scholar14 Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol.10,490–500 (2010).Crossref, Medline, CAS, Google Scholar15 Ephrem A, Chamat S, Miquel C et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood111,715–722 (2008).Crossref, Medline, CAS, Google Scholar16 Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol.127,823–830 e1–e7 (2011).Crossref, Medline, CAS, Google Scholar17 Lombardi G, Sagoo P, Scotta C et al. Cell therapy to promote transplantation tolerance: a winning strategy? Immunotherapy3(Suppl. 4),S28–S31 (2011).Link, Google Scholar18 You S, Candon S, Kuhn C, Bach JF, Chatenoud L. CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes. Adv. Immunol.100,13–37 (2008).Crossref, Medline, CAS, Google Scholar19 Bayry J. Autoimmunity: CTLA-4: a key protein in autoimmunity. Nat. Rev. Rheumatol.5,244–245 (2009).Crossref, Medline, CAS, Google Scholar20 Peters JH, Koenen HJ, Hilbrands LB, Joosten I. Immunotherapy with regulatory T cells in transplantation. Immunotherapy1,855–871 (2009).Link, CAS, Google Scholar21 Bayry J, Siberil S, Triebel F, Tough DF, Kaveri SV. Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov. Today12,548–552 (2007).Crossref, Medline, CAS, Google Scholar22 Iellem A, Mariani M, Lang R et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med.194,847–853 (2001).Crossref, Medline, CAS, Google Scholar23 Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW. Recruitment of FoxP3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J. Exp. Med.201,1037–1044 (2005).Crossref, Medline, CAS, Google Scholar24 Sather BD, Treuting P, Perdue N et al. Altering the distribution of FoxP3(+) regulatory T cells results in tissue-specific inflammatory disease. J. Exp. Med.204,1335–1347 (2007).Crossref, Medline, CAS, Google Scholar25 Yuan Q, Bromley SK, Means TK et al. CCR4-dependent regulatory T cell function in inflammatory bowel disease. J. Exp. Med.204,1327–1334 (2007).Crossref, Medline, CAS, Google Scholar26 Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med.10,942–949 (2004).Crossref, Medline, CAS, Google Scholar27 Gobert M, Treilleux I, Bendriss-Vermare N et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res.69,2000–2009 (2009).Crossref, Medline, CAS, Google Scholar28 Toulza F, Nosaka K, Tanaka Y et al. Human T-lymphotropic virus Type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. J. Immunol.185,183–189 (2010).Crossref, Medline, CAS, Google Scholar29 Bayry J, Tchilian EZ, Davies MN et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc. Natl Acad. Sci. USA105,10221–10226 (2008).Crossref, Medline, CAS, Google Scholar30 Davies MN, Bayry J, Tchilian EZ et al. Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One4,e8084 (2009).Crossref, Medline, Google Scholar31 Kang S, Xie J, Ma S, Liao W, Zhang J, Luo R. Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology215,153–162 (2010).Crossref, Medline, CAS, Google Scholar32 Pere H, Montier Y, Bayry J et al. A CCR4 antagonist combined with vaccines induce antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood118,4853–4862 (2011).Crossref, Medline, CAS, Google Scholar33 Montane J, Bischoff L, Soukhatcheva G et al. Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets. J. Clin. Invest.121,3024–3028 (2011).Crossref, Medline, CAS, Google Scholar34 von Herrath M. Combination therapies for Type 1 diabetes: why not now? Immunotherapy2,289–291 (2010).Link, Google ScholarFiguresReferencesRelatedDetailsCited ByCD4+CCR8+ Tregs in ovarian cancer: a potential effector Tregs for immune regulation10 November 2023 | Journal of Translational Medicine, Vol. 21, No. 1Immune-mediated inflammatory diseases: progress in molecular pathogenesis and therapeutic strategies10 January 2014 | Expert Review of Clinical Immunology, Vol. 9, No. 4 Vol. 4, No. 1 STAY CONNECTED Metrics Downloaded 209 times History Published online 13 December 2011 Published in print January 2012 Information© Future Medicine LtdKeywordsautoimmune diseasesCCL17CCL22CCR4CD4+CD25+FoxP3+ T cellschemokineimmunotherapyTregsAcknowledgementsThe author apologizes to those whose publications could not be cited here because of space limitation.Financial & competing interests disclosureJ Bayry is supported by grants from the Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie, Université Paris Descartes, ANR-BLANC 2010: HYDROPHOBIN and European Community's Seventh Framework Programme (FP7-2007–2013) under Grant Agreement No. HEALTH-F2-2010-260338-ALLFUN. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download